DarioHealth (NASDAQ:DRIO – Get Free Report) and ADB International Group (OTCMKTS:EQUR – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk.
Profitability
This table compares DarioHealth and ADB International Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DarioHealth | -192.23% | -60.52% | -37.08% |
| ADB International Group | N/A | N/A | N/A |
Valuation & Earnings
This table compares DarioHealth and ADB International Group”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DarioHealth | $22.36 million | 2.41 | -$41.71 million | ($8.88) | -0.83 |
| ADB International Group | N/A | N/A | N/A | N/A | N/A |
ADB International Group has lower revenue, but higher earnings than DarioHealth.
Insider and Institutional Ownership
33.4% of DarioHealth shares are held by institutional investors. 3.5% of DarioHealth shares are held by insiders. Comparatively, 79.6% of ADB International Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of current ratings and target prices for DarioHealth and ADB International Group, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DarioHealth | 1 | 1 | 1 | 0 | 2.00 |
| ADB International Group | 0 | 0 | 0 | 0 | 0.00 |
DarioHealth currently has a consensus target price of $10.50, suggesting a potential upside of 42.28%. Given DarioHealth’s stronger consensus rating and higher possible upside, research analysts clearly believe DarioHealth is more favorable than ADB International Group.
Summary
DarioHealth beats ADB International Group on 5 of the 9 factors compared between the two stocks.
About DarioHealth
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
About ADB International Group
E-Qure Corp., a medical device company, focuses on the development and commercialization of bioelectrical signal therapy (BST) devices. Its BST devices implement patented and proprietary electrical stimulation technologies to treat hard-to-cure wounds and ulcers up to complete closure and/or cure. The company was incorporated in 1988 and is based in New York, New York.
Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.
